Biosergen AB: Biosergen publishes…

Summary of the Interim Report for Q1 2023 2023 2022 2022TSEK Jan-Mar Jan-Mar Jan-Dec Profit/lossOther income 5,315 1,317 5,183Profit/loss before depreciation (EBITDA -5,029 -5,018 -34,129Operating profit/loss before net financials -5,029…

Bulletin from the annual general meeting…

Resolution on adoption of accounts and allocation of the company’s resultThe annual general meeting resolved to adopt the profit and loss statement and balance sheet as well as the consolidated…

Biosergen AB: Biosergen publishes 2022…

Biosergen CEO Peder M. Andersen commented: ”We are pleased to present Biosergen’s annual report for 2022. The most important event during the year was the successfully repeated dose escalation in…

Notice of annual general meeting in…

Right to participate and notice of participation Shareholders wishing to participate in the annual general meeting must: partly be listed in the company’s share register kept by Euroclear Sweden AB…

Biosergen AB: Biosergen - Minskad risk…

Biosergen avser att genomföra en fas 2a-studie för att visa den potential som BSG005 har. I studien ingår testfall med olika svampstammar vid invasiv svampsjukdom hos patienter. Undersökningen kommer att…

Biosergen AB: Biosergen - Reduced risk…

Biosergen intends to conduct a phase 2a study to demonstrate the potential that BSG005 possesses. The study includes testing cases with different fungi strains in invasive fungal disease in patients.…

Biosergen AB: Biosergen publishes…

Summary of the Interim Report for Q4 2022 2022 2021 2022 2021TSEK Oct-Dec Oct-Dec Jan-Dec Jan-Dec Other income 1.964 3.290 5.183 8.573Profit/loss before depreciation (EBITDA) -12.491 -9.876 -39.987 -34.077Operating profit/loss…

Carlsquare: Mrkt BUZZ, Biosergen: Plans…

Carlsquare Equity Research comments on Biosergen’s plans for the next step in clinical development. Read the full comment here. About Carlsquare Carlsquare is a Pan-European research firm and financial advisor,…

Biosergen AB: Biosergen provides Phase 2…

Biosergen is pleased to announce its plans to initiate its first Phase 2 clinical trial towards the end of Q2 2023. The multi-indication, open-label, single-center trial will be conducted at…

Biosergen AB: Biosergen will be…